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Plasminogen is the proenzyme precursor of the
primary fibrinolytic protease plasmin. Circulating
plasminogen, which comprises a Pan-apple (PAp)
domain, five kringle domains (KR1-5), and a serine
protease (SP) domain, adopts a closed, activation-
resistant conformation. The kringle domains mediate
interactions with fibrin clots and cell-surface recep-
tors. These interactions trigger plasminogen to
adopt an open form that can be cleaved and con-
verted to plasmin by tissue-type and urokinase-
type plasminogen activators. Here, the structure of
closed plasminogen reveals that the PAp and SP
domains, together with chloride ions, maintain the
closed conformation through interactions with the
kringle array. Differences in glycosylation alter
the position of KR3, although in all structures the
loop cleaved by plasminogen activators is inacces-
sible. The ligand-binding site of KR1 is exposed
and likely governs proenzyme recruitment to targets.
Furthermore, analysis of our structure suggests that
KR5 peeling away from the PAp domain may initiate
plasminogen conformational change.
INTRODUCTION
The conversion of plasminogen to plasmin is central to tissue re-
modeling and blood clot removal after injury (Lijnen, 2001).
Consequently, patients with severe plasminogen deficiency
(hypoplasminogenmia) typically suffer from a range of difficult-
to-treat inflammatory conditions, including ligneous conjuncti-
vitis, gingivitis, and neural disorders (Mehta and Shapiro, 2008;
Schuster et al., 2007). Outside its function in normal hemostasis,
plasmin plays an important role in tumor metastasis through
degradation of the basement membrane and the extracellular
matrix (Castellino and Ploplis, 2005; Rijken and Lijnen, 2009).
Furthermore, a wide variety of disease-causing bacteria expressvirulence factors that hijack the plasminogen/plasmin system in
order to enhance tissue destruction and pathogen invasiveness
(Sun, 2006; Waisman, 2003). Finally, as a consequence of the
potent fibrinolytic capability of plasmin, the plasminogen system
is an important drug target (Hasumi et al., 2010; Mekkawy et al.,
2009; Ryou et al., 2011), and therapeutic application of plasmin-
ogen activators or inhibitors are used to treat clotting or bleeding
disorders respectively. An emerging role for the utility of plasmin
inhibitors in treating certain cancers is also notable (Ishihara
et al., 2012).
Activation of the plasminogen system is tightly regulated, not
least to prevent development of a systemic fibrinolytic state
or tumor metastasis. Without structural insights, however, the
molecular basis for the conformational activation of plasminogen
after its recruitment to clots or cells remains unclear.
RESULTS AND DISCUSSION
To address this problem, we determined the 2.45 A˚ structure of
the closed conformation of type II human plasminogen, a glyco-
form that contains a single O-linked glycosylation moiety on
Thr346 and that comprises 60% of circulating material. Two
molecules (A and B) are present in the asymmetric unit. Our
description throughout relates to molecule A unless otherwise
stated.
The seven domains (791 amino acids in total) of plasminogen
are loosely clustered in a diamond-shaped zig-zag assembly
(Figure 1A). SAXS analyses confirm that the crystal structure is
similar in overall shape to the conformation of closed plasmin-
ogen in solution (Figure S1). The structure reveals that the
N-terminal PAp domain makes extensive contacts with KR4
and KR5. These interactions include Lys50, Arg68, and Arg70
from the PAp domain interacting with the lysine-binding sites
(LBS) of KR4 and KR5, respectively (Figure 1B). The interactions
made by the PAp domain are known to be critical for maintaining
the closed conformation of plasminogen (Ponting et al., 1992).
Indeed, proteolytic removal of the PAp by plasmin (to form
Lys-plasminogen) results in the molecule adopting the open
conformation (Marshall et al., 1994; Miles et al., 2003; Weisel
et al., 1994). With respect to this latter proteolytic event, theCell Reports 1, 185–190, March 29, 2012 ª2012 The Authors 185
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Figure 1. The Structure of Human Type II Plasminogen and the Interactions that Maintain the Closed Conformation
(A) The overall structure of plasminogen (molecule A). The domains are labeled and colored as follows: Pap, blue; KR1, pink; KR2, yellow; KR3, orange; KR4,
green; KR5, purple; SP, cyan. Chloride ions Cl(1) and Cl(2) are at the KR4/PAp and KR2/SP interface, respectively, and are shown as spheres. Two other chloride
ions, Cl(3) and Cl(4), bind to KR2 and SP domain, respectively. The position of the activation loop (R561) is marked with a red sphere. The LBS of KR1 is marked
with an asterisk (*).
(B) Key interactions made by the PAp domain with KR4 and KR5. K50 blocks the LBS of KR5 and primarily interacts with D518 of the DXD motif, forming an
extremely short salt bridge (2.6A˚). In contrast, D516 is 4 A˚ away. Arg70 coordinates both KR4 and KR5 through interactions with D413 and D534, respectively.
Arg68 blocks the LBS of KR4, interacting with both D411 and D413 of the DXDmotif. A chloride ion, Cl(1), forms hydrogen bonds with the backbone nitrogen (not
shown) of R68 on the PAp domain, as well as the sidechains of R426 and K392. In the structure of KR4 bound to a C-terminal lysine analog (Wu et al., 1991), both
R426 and K392 in KR4 function in binding the carboxylic acid group.
(C) Interface among KR4, the KR3/KR4 linker, the activation loop, and the SP domain. KR4 makes several interactions with the KR3/KR4 linker, mostly centered
around residues 350–352. In contrast, only a single interaction between E554 of the activation loop and the backbone nitrogen of the KR3/KR4 linker residue V355
is apparent. Interestingly, T352 and P353 are mutated in plasminogen deficiency.
(D) The SP/KR2 interface – K708 from the SP domain is inserted into the LBS of KR2 and forms a salt bridge with both D219 and E221 of the DXEmotif. A chloride
ion, Cl(2), is coordinated by R234,W235 and the backbone nitrogen of K708. A salt bridge between R234 and E706 serves to tie the distal end of the LBS to the SP
domain. D219 and R234 are both mutated in human disease (Schuster et al., 2007).cleavage site in the N terminus (Lys77) that is targeted by
plasmin is buried in the closed conformation, suggesting that
some conformational rearrangement likely precedes the produc-
tion of Lys-plasminogen.
In addition to the interactions made with the PAp domain, KR4
forms a further, unusual interface with the activation loop and
the SP domain (Figure 1C). These interactions serve to trap the
KR3/KR4 linker region in a critical position that protects the
proenzyme from unwanted activation, a feature that is discussed
in more detail later (Figure 1C). Furthermore, two loops (672–678
and 703–713) on the SP domain form extensive interactions
with the KR2 domain (Figure 1D). Lys708 is of particular impor-
tance in this regard, because it interacts with the LBS of KR2.
Structural mapping of human mutations associated with hypo-
plasminogenemia reveals that several disease-relatedmutations
would be anticipated to interfere with the KR2/SP interface as
well as other interdomain contacts (Schuster et al., 2007)
(Figure S2).186 Cell Reports 1, 185–190, March 29, 2012 ª2012 The AuthorsPlasminogen was purified and crystallized in 150 mM
sodium chloride. Plasma chloride plays an important role in
stabilizing closed plasminogen (Urano et al., 1987). Accordingly,
we observed a single chloride ion bound at both the KR4/PAp
and the SP/KR2 interfaces (Figure 1B and 1D). A third and fourth
Cl are coordinated by KR2 and the SP domain, respectively
(Figure 1A), but these do not mediate interdomain interactions.
In contrast to the other kringle domains, KR3 contains a muta-
tion in its LBS (DXD/E motif to DXK) and does not bind lysine
in vitro (Christen et al., 2010). Its role in the broader context of
the plasminogenmolecule thus remains unclear. In our structure,
and as previously observed in the structure of angiostatin (Abad
et al., 2002), KR3 forms a significant interface (including a disul-
phide bond) with KR2. These interactions serve to orient KR3
such that it is positioned next to the SP domain. Only one signif-
icant interaction is made at the KR3/SP interface: a hydrogen
bond between the d-N of Asn289 on KR3 and the sidechain of
Glu714 from the SP domain (Figure 2A). This interaction is,
Figure 2. The Influence of the N-Linked Glycosylation on Plasmin-
ogen Structure
(A) The KR3/SP interface. A hydrogen bond is formed between the d-N of N289
on KR3 and the sidechain of E714 from the SP domain. Tyr713 from the SP
domain is also at the interface.
(B) The low-resolution structure of type I plasminogen. KR3 is not visible in
electron density; its position in type II plasminogen is indicated by an orange
ellipse.
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Figure 3. The Activation Loop Is Shielded in the Closed State
(A) The activation loop (pink) and cleavage site (R561/V562—in stick) is pro-
tected by the position of the KR3/KR4 linker sequence. O-linked glycosylation
on T346 in the KR3/KR4 linker further shields R561. The position of KR4, KR3,
and the SP domain is shown.
(B) Superposition (made on the respective protease domains) of the structure
of closed plasminogen with the previously reported structure of the mini-
plasmin/Streptokinase complex (PDB identifier 1BML) (Wang et al., 1998).
Streptokinase (in red) binds in a fashion that avoids contact with the kringle
array. The protease domain of the streptokinase complex structure is not
shown.however, of interest, because Asn289 is N-glycosylated in type I
plasminogen, a distinct glycoform that comprises 40% of
circulating material (Booth and Bachmann, 2005). Different
patterns of glycosylation in plasminogen have important biolog-
ical consequences—type I plasminogen has 10-fold less affinity
for cells in comparison to the type II counterpart (Gonzalez-
Gronow et al., 2002). Conversely, type I plasminogen appears
to function more efficiently than type II in the context of fibrin
clots (Takada et al., 1985).
To investigate the structural consequences of differing
patterns of glycosylation on plasminogen, we determined the
structure of the type I plasminogen (Figure 2B). The molecule
was crystallized in a different space group and extensive rounds
of optimization were required to obtain crystals that diffracted to
5.2 A˚ resolution. The resulting model, which comprised a single
molecule that was present in the asymmetric unit, was interpret-
able only in the context of backbone atoms. However, these data
reveal that the positions of six of the seven domains are the same
as in molecule A. The exception, KR3, is no longer visible in elec-
tron density. These data suggest either that the low resolution of
these data precludes our building KR3 in a new position or that
glycosylation induces significant mobility in this region with
respect to the remainder of the structure. In support of the latter
idea, disorder in KR3 has been reported in the high-resolution
structure of the first three kringle domains of plasminogen
(angiostatin) bound to a peptide derived from the bacterial viru-lence factor PAM (Cnudde et al., 2006). Taken together, these
data help to explain the observation that type I plasminogen is
more conformationally labile and more readily able to adopt
the open conformation than its type II counterpart (Mori et al.,
1995). Furthermore it is suggested that precise positioning of
KR3 may be required for efficient recruitment of closed plasmin-
ogen to the cell surface.
The conversion of plasminogen to plasmin requires cleavage
of the activation loop at the Arg561/Val562 bond by proteases
such as tissue-type plasminogen activator (tPA) or urokinase-
type plasminogen activator (uPA) or by plasmin itself (Lijnen,
2001). Currently, however, it is unclear how the proenzyme
form is protected from unwanted proteolysis. Our data reveal
that the activation sequence is shielded by the position of the
KR3/KR4 linker (Figure 1C and 3A). The latter region runs in an
antiparallel direction 8 A˚ away from the activation loop andwould
predictably interfere with the canonical docking of an activating
protease. The O-linked glycosylation moiety on Thr346, which is
present in all plasminogen glycoforms (Hayes and Castellino,
1979a, b; Hayes andCastellino, 1979c), further serves to partially
shield the Arg561/Val562 bond and indeed forms a polarCell Reports 1, 185–190, March 29, 2012 ª2012 The Authors 187
Figure 4. Kringle 5 Has Mobility with Respect to the PAp Domain
(A) Molecules A and B were superposed on PAp, KR1-4, and the SP domain.
The figure illustrates the position of KR5 in molecule A (purple) with respect to
molecule B (Red). The PAp domain of molecule B is also highlighted (blue).
KR5 in molecule B has swung away from the PAp domain such that K50 (in
stick, and labeled) is partially disordered but no longer docked in the KR5 LBS.
(B) Side-by-side comparison of the intact KR5 from molecule A and the
partially disordered (start of such regions indicated by *) KR5 in molecule B.
The two domains are similarly orientated. Disulphide bonds (yellow stick) are
shown in each structure.interaction with the sidechain of Arg561. We also note that the
position of KR3 in type II plasminogen might serve as a physical
barrier to activating proteases (Figure 3A). Thus, plasminogen
has evolved a sophisticated mechanism to guard against unde-
sirable activation by proteases. Despite these safeguards,
superposition experiments reveal that bacterial virulence factors
such as streptokinase, which can readily activate the closed
conformer of plasminogen (Parry et al., 2000; Wang et al.,
1998), can bind to the SP domain in a way that neatly avoids
the kringle array (Figure 3B).
Closed plasminogen is known to contain a high-affinity LBS
that is important for interaction with C-terminal lysine residues
present in fibrin clots or cell-surface plasminogen receptors
(Ponting et al., 1992). A central question to plasminogen recruit-
ment to the target sites is related to the identity of this high-
affinity site. Four out of the five kringle domains (KR1, KR2,
KR4, and KR5) are able to bind lysine when isolated in vitro.
These studies also reveal that both KR1 and KR4 contain an188 Cell Reports 1, 185–190, March 29, 2012 ª2012 The AuthorsLBS that exhibits high affinity for a C-terminal lysine moiety.
Our structure reveals that, consistent with biochemical observa-
tions (Ponting et al., 1992), only the LBS of KR1 is unprotected in
closed plasminogen (Figure 1A). We therefore suggest that this
domain mediates initial recruitment to fibrin or the cell surface
(Castellino and Ploplis, 2005).
It is suggested that after recruitment to targets, additional
lysine kringle interactions trigger a major conformational change
such that plasminogen switches from the compact closed state
to an open extended form. The latter state is best modeled by an
extended array of the seven domains (Castellino and Ploplis,
2005). Lysine binding is essential for this interaction, as evi-
denced by the effect of therapeutically useful lysine analogs
such as epsilon-aminocaproic acid (EACA) or tranexamic acid
(TXA). Structures of isolated kringle domains in the presence or
absence of lysine analogs suggest that ligand interaction with
KR1 does not promote any dramatic structural rearrangement.
It is therefore likely that a separate region of the molecule to
the recruitment site must be responsible for triggering plasmin-
ogen conformational change (Ponting et al., 1992). Biochemical
studies suggest that the LBS of KR4 or KR5 may represent
this conformational trigger; however, these sites are apparently
blocked in closed plasminogen (Christensen and Mølgaard,
1992; Va´li and Patthy, 1982).
Our structure provides insight into this problem. Analysis of the
type II plasminogen structure reveals that the second molecule
(B) in the asymmetric unit has undergone significant conforma-
tion change in comparison to molecule A (Figure 4A). Specifi-
cally, KR5 has swung away from the core of the plasminogen
structure, this movement resulting in a 7 A˚ shift away from
the PAp. This change transiently exposes the KR5 LBS such
that it could interact with lysine-containing ligands. These
observations thus support the idea that KR5 is crucial for trig-
gering plasminogen conformational change (Hasumi et al.,
2010; Marshall et al., 1994; Thorsen, 1992). We further suggest
that the structure of molecule B resembles one of the reported
intermediates upon the pathway of plasminogen conformational
change (Marshall et al., 1994).
Our structural data suggest a possible reason underlying
the mobility in KR5. In the fully closed conformer (molecule A),
Lys50 from the PAp domain primarily interacts with one
(Asp518) of the two aspartic acids of the KR5 lysine binding
DXD motif, forming a strong salt bridge (Figure 1C). In contrast,
the second aspartic acid (Asp516) of the DXD motif is 4 A˚
away. Analysis of the structure of a kringle in complex with
EACA (PDB 2PK4) (Wu et al., 1991) reveals that a typical
canonical kringle-lysine interaction involves two short ionic inter-
actions (2.5 A˚) with both aspartic acid residues of the DXD
motif. We therefore suggest that the PAp domain makes an
imperfect interaction with KR5 that is insufficient to stably tether
this domain to the closed plasminogen core. The resulting
mobility in KR5 thus most likely represents the ‘‘Achilles heel’’
of closed plasminogen to activating ligands. Once the KR5
LBS is exposed, interactions with lysine residues present in
binding partners may irreversibly set the molecule on the
pathway of conformational change. Additional conformational
events, most likely involving disruption of the KR4 or KR2 inter-
face, would predictably culminate in the molecule falling apart.
Table 1. Data Collection and Refinement Statistics
Type I
Plasminogena
Type II
Plasminogena
Data collection
Space group P43212 P3221
No mol/au 1 2
Cell dimension: a, b, c (A˚) 110, 110, 234 144.6, 144.6, 233.7
Cell dimension: a, b, g () 90, 90, 90 90, 90, 120
Resolution (A˚) 99.70 (5.2) 125.25 (2.45)
Rmerge /Rpim 17.4 (80.3)/
7.8 (36.1)
17.5 (77.5)/
7.1 (35.1)
I/sI 6.8/2.4 9.2/2.3
Completeness (%) 92.8 (91.3) 99.8 (98.9)
Redundancy 5.4 (5.4) 6.9 (5.4)
Refinement
No. reflections (work/free) 5,275/231 104,035/5,236
Rwork/ Rfree 26.3/31.3 18.9/21.5
No. atoms: protein 5,282 11,699
No. atoms: ligand/ion 0 111
No. atoms: water 81 1,436
B-factors: Wilson 140b 45.0
B-factors: protein 70.7 33.13
B-factors: ligand/ion - 76.55
B-factors: water 70.8 37.23
R.m.s deviations:
bond lengths (A˚)
0.007 0.007
R.m.s deviations:
bond angles ()
0.82 0.96
MolProbity analysis:
Ramachandran outliers
1.33% 0.07%
MolProbity analysis:
Ramachandran favored
92.01% 96.77%
MolProbity score 2.07 (100th
percentile)
1.71 (98th
percentile)
aHighest-resolution shell is shown in parenthesis.
bCalculated with the use of TRUNCATE and data to 4.1A˚ (Rupp, 2009).Interestingly, only one direct polar interaction between the KR3/
KR4 linker and the far N-terminal end of activation loop is
apparent (Figure 3A). Thus, once conformational change is initi-
ated; the KR3/4 linker would be anticipated to move away from
the activation loop, and expose the latter region for cleavage
by activating proteases.
Interestingly, an unanticipated consequence of KR5 release
from the PAp domain is that the former domain becomes partially
disordered, particularly around the C462/Cys541 disulphide
bond (Figure 4B). Indeed, this disulphide is broken in molecule
B, possibly as a consequence of exposure of the crystals to
synchrotron radiation. These data, however, provide an explana-
tion for the observed susceptibility of KR5 to disulphide reduc-
tion by phosphoglycerate kinase (Lay et al., 2000) as well as
the cleavage events that take place within this domain during
the production of the potent angiogenic factor angiostatin
(KR1-4) and miniplasmin (KR5-SP) (Christensen et al., 1979).To conclude, we suggest that KR1 and KR5 in the closed plas-
minogen govern the proenzyme recruitment and initiation of
conformational change, respectively. The implication of this
model is that plasminogen substrates and activators must
present precisely positioned and spatially distinct lysine residues
in order to activate the plasminogen system. Such a mechanism
would provide a safeguard against casual or unwanted activa-
tion of the plasminogen/plasmin system.
EXPERIMENTAL PROCEDURES
Human type I and type II plasminogen was purified from plasma as previously
described (Hayes and Castellino, 1979c). Type I plasminogen was crystallized
in 2 M sodium formate, type II in 0.1 M sodium citrate, 0.2 M sodium acetate,
polyethylene glycol 1,000, polyethylene glycol 8,000 [pH 5–6]. Data were
collected at the Australian Synchrotron Micro Crystallography MX2 beamline.
A combination of anisotropic diffraction and radiation damage explains the
higher overall Rmerge than expected (17.5%) for data of this resolution. The
structure was determined with the use of PHASER and the structures of
1QRZ (Peisach et al., 1999), 1KRN (Stec et al., 1997), 5HPG (Chang et al.,
1998), and 1LOS (Christen et al., 2010) as molecular replacement probes.
Model building was performed with COOT, and refinement was performed
with REFMAC (Murshudov et al., 1997) and BUSTER (Bricogne et al., 2011).
The final model of type II plasminogen has an Rfree of 21.52% and displays
excellent stereochemistry. The structure of type I plasminogen was solved
with PHASER, and the best solution and electron density map were obtained
by using the structure of type II plasminogen without the KR3 (RFZ = 8.9,
TFZ = 22.9, and LLG= 288). The structurewas refinedwith BUSTERwith a final
Rfree of 31.13%. Further modeling and phasing experiments failed to obtain
a solution for KR3. Data collection and refinement statistics are summarized
in Table 1. The PDB identifiers for type I and type II plasminogen are 4DUU
and 4DUR, respectively.
Small-angel X-ray scattering (SAXS) experiments were performed at the
Australian Synchrotron SAXS/WAXS beamline with the use of a fix energy
of 12 keV and a camera length of 1.6 M on a protein concentration of
0.5 mg/ml and 0–50 mM EACA. Data were processed with PRIMUS (Konarev
et al., 2003), and the radius of gyration (Rg) was evaluated via Guinier approx-
imation. Ab initio models were generated with DAMMIN (Svergun, 1999).
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